News and Announcements
SUDA Update: Funding for Second Phase III Study of ArTiMist™, BIO-Europe Spring International Partnering Conference & More
- Published April 19, 2016 10:58AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
19th Apriul 2016, ASX Announcement
SUDA LTD (ASX: SUD), a leader in oro-mucosal drug delivery, today announces an update on its business development activities. The Company is in advanced negotiations with multiple pharmaceutical companies regarding licensing its first-in-class oral sprays in a variety of countries. Subject to successful contact negotiations, SUDA aims to finalise agreements within the next few months. Discussions with philanthropic groups and other providers on non-dilutive funding for a second Phase III study of ArTiMist™ in paediatric malaria are also progressing.
The business development team attended the BIO-Europe Spring international partnering conference, which was held in Stockholm, Sweden, on 4-6 April 2016. The team has one-to-one meetings with over 30 pharmaceutical companies.
To view the full article please click on the button below.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
